Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Age is strictly a case of mind over matter. If you don't mind, it doesn't matter"
Surely there are other things that I'm not too young to know and you're not old enough to forget :)
No need to, I have this (Besides, it emphasizes the wrinkles)
You've made us all very proud of your jumping ability Dubi. I suppose you know nothing of this
You're not going anywhere before you finish all your homework young man.
Just pulling your leg Dubi, I know this is more like you:
http://bp3.blogger.com/_xmvFPkV-WfQ/RicTD607sqI/AAAAAAAAAAU/B6XkEBSi1tE/s1600-h/mban656l.jpg
I thought you'll make me beg :)
Problem is that when I say that Dubi is the only living soul who listens and leaps to bed.
"I have already met two of this boardmembers, hopefully more
meetings will take place in the future."
Should I take a number or just stand at the end of the queue?
Good. I'm glad we settled that one.
Now, tomorrow is a school day and we've long passed our bed time.
It's alright, we all have our moments
What the guys were trying to tell you in their own gentle way is that cramps is American slang for period pains.
I don't deserve this warm welcome Dubi, but on the other hand, I have cramps and I don't deserve that either.
I'm afraid they simply forgot to take their medications.
The difficulty with chatting here is that it's very different from the ones I've had of late, which have mostly been with trees and pebbles.
We'll know better on Friday after the court will rule on Protonix.
Yanay is a bit more conservative (for the time being).
I'm not so convinced that TEVA will launch Protonix at-risk, since the patent case is strong, I think they will rather have some kind of agreement with Wyeth instead.
Cell Cure is TEVA's second investment in the stem cell field, the other one which in my view is the more promising one is in Gamida Cell.
BiolineRX-
Nice call (good for me), BiolineRX has bounced from 385 to 4515NIS while I was away!
As noted by Praveen, PLX was falling on some good news, still having an irrational 1.7B market cap. Nothing surprises me with this stock but I was expecting PLX's insiders to dump shares in the near future. They also are worried about the stock's movements and price and need it to be rational in order to raise money via offering common stocks to the public. As soon as insiders will sell, price should stabilize and they will be able to issue more stocks and raise more cash.
I do like Procognia's platform and want to see their work progress into clinical trials.
Biolit-
"Obesity drug does work for some"
I see that the stock bounced when I was away, I know you're not holding, still this is fun:
They are trying a statistical outwitting in order to find a shred of significant effect for the drug.
Moreover, they did not even wait for the analysis to be complete, and went public with farfetched conclusions that if you look at their data will make you laugh. I know you will not look at the data so this will deal with the laughter part:
Will log off soon, be back sometime next week
depends on the weight and the wind
BPA
Don't know when does the formulation patent run out, I think they are using Antares Pharma's formolation. But since LibiGel is bioidentical testosterone, I don't see what will stop physicians from prescribing generic versions of similar compounds to treat FSD. So far, as reported by BDY, Elestrin (BPA's first product), is not selling very well and Libigel will face the same sort of generic challengers IMO.
Why not? All it takes is a hurricane and we're good to go.
Biosante
{I remember reading some posts about them here which were not very optimistic, so here is a different view}
Oppenheimer Starts BioSante at 'Buy'
Thursday August 23, 12:58 pm ET
Oppenheimer Starts BioSante at 'Buy,' Sees Female Testosterone Gel LibiGel Being Approved
NEW YORK (AP) -- Oppenheimer analyst Kevin DeGeeter started coverage of BioSante Pharmaceuticals Inc. with a 'Buy' rating, saying he is optimistic that LibiGel, the company's testosterone gel for female hypoactive sexual desire disorder, will generate income in the next 12 to 18 months through either a commercial partnership or sale of the company.
Late Wednesday, DeGeeter said LibiGel, which is in late-stage studies, has sales potential of more than $500 million, given the poorly served market of 40 million women in the U.S.
Currently, investors aren't focusing on LibiGel's potential because of uncertainty about how long safety follow-up studies have to continue before LibiGel is eligible for FDA approval, DeGeeter said. But he things the regulatory landscape involving hormone replacement therapy is evolving, and believes BioSante will find a partner to validate its regulatory pathway and mitigate development risk.
In addition, DeGeeter expects royalties from hot flash treatment Elestrin and partnerships with Teva and Pantarhei BioScience to defray the rate at which BioSante spends cash and provide for a healthy core business.
He also notes that CEO Stephen Simes and CFO Philip Donenberg have a history of building and successfully selling businesses, and after nine years with BioSante, DeGeeter thinks the company's management team and board would be open to an appropriate exit strategy.
Shares of BioSante rose 4 cents to $5.59 in afternoon trading. The stock has ranged between $1.48 and $8 over the past year. DeGeeter's $9 price target implies 61 percent upside to current prices.
http://biz.yahoo.com/ap/070823/biosante_analyst_note.html?.v=1&printer=1
Depends on your weight and the wind.
Need a ride?
Know what you mean, I'm very good at being a lady but being a witch is much more fun.
Shall we have tea now or would you rather one more ride on the broom?
Blame my being here on Dubi.
As for the pic, being first isn't always that good ha?
Biologically speaking, if something bites, it is more likely to be female :)
Don't know, I lack the equipment.
Pick your choice, as long as you don't let them interfere with your education :)
Ok I give up, here's what happened:
You wrote:
"Is there a site where I can get a translation of this?"
And I was going to answer:
yes actually there is, it's called university.
And then I thought it sounds as if I'm patronising and that you might be offended.
To make things worse, I noticed I was replying myself so I deleted and considered that the act of the divine censor who saved me from making an ass of myself.
Never before so little words had so much impact.
This is the art of antiwriting.
No Sherlock, I ran out of that on the last mission.
I simply wrote something I thought was too offensive.
FDA approves generic herpes drug
FDA approves Teva's generic version of Novartis' herpes drug Famvir; drugmakers still face day in court.
By Aaron Smith, CNNMoney.com staff writer
August 24 2007: 12:15 PM EDT
NEW YORK (CNNMoney.com) -- Teva Pharmaceuticals, the top-selling generic drugmaker in the world, said the FDA approved its generic version of Novartis' genital herpes drug Famvir.
But Novartis will still have its day in court.
Jerusalem-based Teva (up $0.71 to $41.56, Charts) said the Food and Drug Administration granted it 180-day exclusivity to produce a low-cost version of Novartis' (up $0.16 to $52.72, Charts) Famvir.
After the period of exclusivity ends, Famvir is fair game for other generic drugmakers, like Mylan Laboratories (up $0.12 to $15.14, Charts) and Barr Laboratories (up $0.16 to $52.22, Charts) of the U.S. and Ranbaxy Pharmaceuticals (down $0.18 to $8.48, Charts) and Dr. Reddy's Laboratories of India.
Famvir totaled $200 million in U.S. sales for Novartis during the 12 months ended June 30, 2007, according to Teva. But revenues for brand-name drugs plunge once they're pressured by generic competition.
Teva still faces a legal hurdle before launching its low-cost herpes pill, also known by its generic name, famciclovir. Swiss drugmaker Novartis sued Teva for patent infringement in 2005, and a hearing is scheduled for Sept. 5 in the U.S. District Court in New Jersey. Teva said it won't launch a generic version of Famvir until that hearing is concluded.
Famvir competes with GlaxoSmithKline's (up $0.45 to $52.03, Charts) herpes drug Valtrex.
http://money.cnn.com/2007/08/24/news/companies/herpes/index.htm?source=yahoo_quote
Obviously because they are not attached to her.